The Relationship between Antioxidant Activity of Hyper Density Lipoprotein and Microalbuminuria in Patients with Hypertension_West China Medical Journal

Authors：

 ZHOUXiao-yan , JIANGXi , WANGSi ,  CHENXiao-ping , PANPei

Department of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding?author：

CHENXiao-ping, Email: xiaopingchen11@126.com

Keywords：

Hypertension; Hyper density lipoprotein; Paraoxonase; Microalbuminuria

DOI：

10.7507/1002-0179.20140142

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To discuss the relationship between microalbuminuria (MAU) and antioxidant activity of plasma hyper density lipoprotein (HDL) in hypertensive patients, and investigate whether MAU could be a predictor of HDL antioxidant activity. Method From December 2007 to March 2009, sixty consecutive primary hypertensive patients from the inpatient and outpatient departments of West China Hospital and Sichuan Electric Power Central Hospital were included in the study, and 30 healthy volunteers served as controls. MAU, plasma HDL and paraoxonase (PON1) activity were tested. Results PON1 activity was lower in hypertensive patients than the controls (P<0.05), and this degree of decline was positively related to MAU (P<0.05). Conclusion MAU reflects PON1 activity in hypertensive patients and can be a predictor to judge plasma HDL function in patients with hypertension.

Citation： ZHOUXiao-yan, JIANGXi, WANGSi, CHENXiao-ping, PANPei. The Relationship between Antioxidant Activity of Hyper Density Lipoprotein and Microalbuminuria in Patients with Hypertension. West China Medical Journal, 2014, 29(3): 470-473. doi: 10.7507/1002-0179.20140142 Copy

1.	Lloyd-Jones DM, Evans JC, Larson MG, et al. Cross-classification of JNC Ⅵ blood pressure stages and risk groups in the Framingham Heart Study[J]. Arch Intern Med, 1999, 159(18):2206-2212.
2.	Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies[J]. Circulation, 1989, 79(1):8-15.
3.	Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment[J]. Circulation, 1992, 85(1):37-45.
4.	Ansell BJ, Navab M, Hama S, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment[J]. Circulation, 2003, 108(22):2751-2756.
5.	Gerstein HC, Mann JF, Pogue J, et al. Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators[J]. Diabetes Care, 2000, 23(Suppl 2):B35-B39.
6.	Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy:the life study[J]. Ann Intern Med, 2003, 139(11):901-906.
7.	Ravera M, Ratto E, Vettoretti S, et al. Microalbuminuria indicates subclinical cerebrovascular damage in patients with essential hypertension[J]. J Nephrol, 2002, 15(5):519-524.
8.	Chobanian AV, Bakris GL, Black HR. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 report[J]. Hypertension, 2003, 12(4):31-32.
9.	Rodbard HW, Blonde L, Braithwaite SS, et al. American association of clinical endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus[J]. Endocr Pract, 2007, 13(Suppl 1):1-68.
10.	Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism[J]. Am J Hum Genet, 1983, 35(6):1126-1138.
11.	Teiber JF, Draganov DI, La Du BN. Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3[J]. Biochem Pharmacol, 2003, 66(6):887-896.
12.	伍悅蕾, 陳曉平, 蔣凌云, 等. 高血壓病患者高密度脂蛋白抗低密度脂蛋白氧化能力降低[J]. 中國動脈硬化雜志, 2007, 15(12):909-912.
13.	郭建政, 譚子新, 尚可, 等. 血清對氧磷酯酶1活性與2型糖尿病合并高血壓的關系[J]. 中國醫藥導報, 2012, 9(10):46-47, 50.
14.	Zheng L, Nukuna B, Brennan ML, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease[J]. J Clin Invest, 2004, 114(4):529-541.
15.	Arnl?v J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals:the Framingham Heart Study[J]. Circulation, 2005, 112(7):969-975.
16.	H?rner D, Fliser D, Klimm HP, et al. Albuminuria in normotensive and hypertensive individuals attending offices of general practitioners[J]. J Hypertens, 1996, 14(5):655-660.
17.	李明洲, 鄧開伯, 曾學寨, 等. 高血壓患者微量白蛋白尿的陽性率及相關因素[J]. 中國心血管雜志, 1998, 3(6):405-407.
18.	高欣, 吳偉, 鮑利民, 等. 原發性高血壓、冠心病患者尿微量白蛋白陽性率及其相關因素[J]. 中國衛生檢驗雜志, 2008, 18(1):5-46, 59.
19.	Ishibashi M, Hiasa K, Zhao Q, et al. Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling[J]. Circ Res, 2004, 94(9):1203-1210.
20.	Suematsu M, Suzuki H, Delano FA, et al. The inflammatory aspect of the microcirculation in hypertension:oxidative stress, leukocytes/endothelial interaction, apoptosis[J]. Microcirculation, 2002, 9(4):259-276.
21.	Victorino GP, Newton CR, Curran B. Dose-dependent actions and temporal effects of angiotensin Ⅱ on microvascular permeability[J]. J Trauma, 2003, 55(3):527-530.

1. Lloyd-Jones DM, Evans JC, Larson MG, et al. Cross-classification of JNC Ⅵ blood pressure stages and risk groups in the Framingham Heart Study[J]. Arch Intern Med, 1999, 159(18):2206-2212.
2. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies[J]. Circulation, 1989, 79(1):8-15.
3. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment[J]. Circulation, 1992, 85(1):37-45.
4. Ansell BJ, Navab M, Hama S, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment[J]. Circulation, 2003, 108(22):2751-2756.
5. Gerstein HC, Mann JF, Pogue J, et al. Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators[J]. Diabetes Care, 2000, 23(Suppl 2):B35-B39.
6. Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy:the life study[J]. Ann Intern Med, 2003, 139(11):901-906.
7. Ravera M, Ratto E, Vettoretti S, et al. Microalbuminuria indicates subclinical cerebrovascular damage in patients with essential hypertension[J]. J Nephrol, 2002, 15(5):519-524.
8. Chobanian AV, Bakris GL, Black HR. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 report[J]. Hypertension, 2003, 12(4):31-32.
9. Rodbard HW, Blonde L, Braithwaite SS, et al. American association of clinical endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus[J]. Endocr Pract, 2007, 13(Suppl 1):1-68.
10. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism[J]. Am J Hum Genet, 1983, 35(6):1126-1138.
11. Teiber JF, Draganov DI, La Du BN. Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3[J]. Biochem Pharmacol, 2003, 66(6):887-896.
12. 伍悅蕾, 陳曉平, 蔣凌云, 等. 高血壓病患者高密度脂蛋白抗低密度脂蛋白氧化能力降低[J]. 中國動脈硬化雜志, 2007, 15(12):909-912.
13. 郭建政, 譚子新, 尚可, 等. 血清對氧磷酯酶1活性與2型糖尿病合并高血壓的關系[J]. 中國醫藥導報, 2012, 9(10):46-47, 50.
14. Zheng L, Nukuna B, Brennan ML, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease[J]. J Clin Invest, 2004, 114(4):529-541.
15. Arnl?v J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals:the Framingham Heart Study[J]. Circulation, 2005, 112(7):969-975.
16. H?rner D, Fliser D, Klimm HP, et al. Albuminuria in normotensive and hypertensive individuals attending offices of general practitioners[J]. J Hypertens, 1996, 14(5):655-660.
17. 李明洲, 鄧開伯, 曾學寨, 等. 高血壓患者微量白蛋白尿的陽性率及相關因素[J]. 中國心血管雜志, 1998, 3(6):405-407.
18. 高欣, 吳偉, 鮑利民, 等. 原發性高血壓、冠心病患者尿微量白蛋白陽性率及其相關因素[J]. 中國衛生檢驗雜志, 2008, 18(1):5-46, 59.
19. Ishibashi M, Hiasa K, Zhao Q, et al. Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling[J]. Circ Res, 2004, 94(9):1203-1210.
20. Suematsu M, Suzuki H, Delano FA, et al. The inflammatory aspect of the microcirculation in hypertension:oxidative stress, leukocytes/endothelial interaction, apoptosis[J]. Microcirculation, 2002, 9(4):259-276.
21. Victorino GP, Newton CR, Curran B. Dose-dependent actions and temporal effects of angiotensin Ⅱ on microvascular permeability[J]. J Trauma, 2003, 55(3):527-530.

West China Medical Journal

The Relationship between Antioxidant Activity of Hyper Density Lipoprotein and Microalbuminuria in Patients with Hypertension

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content